首页> 美国卫生研究院文献>The International Journal of Angiology : Official Publication of the International College of Angiology Inc >Fibrin Sheath Angioplasty: A Technique to Prevent Superior Vena Cava Stenosis Secondary to Dialysis Catheters
【2h】

Fibrin Sheath Angioplasty: A Technique to Prevent Superior Vena Cava Stenosis Secondary to Dialysis Catheters

机译:纤维蛋白鞘血管成形术:一种预防继发于导管的上腔静脉狭窄的技术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Fibrin sheaths are a heterogeneous matrix of cells and debris that form around catheters and are a known cause of central venous stenosis and catheter failure. A total of 50 cases of central venous catheter fibrin sheath angioplasty (FSA) after catheter removal or exchange are presented. A retrospective review of an outpatient office database identified 70 eligible patients over a 19-month period. After informed consent was obtained, the dialysis catheter exiting the skin was clamped, amputated, and a wire was inserted. The catheter was then removed and a 9-French sheath was inserted into the superior vena cava, a venogram was performed. If a fibrin sheath was present, angioplasty was performed using an 8 × 4 or 10 × 4 balloon along the entire length of the fibrin sheath. A completion venogram was performed to document obliteration of the sheath. During the study, 50 patients were diagnosed with a fibrin sheath, and 43 had no pre-existing central venous stenosis. After FSA, 39 of the 43 patient's (91%) central systems remained patent without the need for subsequent interventions; 3 patients (7%) developed subclavian stenoses requiring repeat angioplasty and stenting; 1 patent (2.3%) developed an occlusion requiring a reintervention. Seven patients with prior central stenosis required multiple angioplasties; five required stenting of their central lesions. Every patient had follow-up fistulograms to document long-term patency. We propose that FSA is a prudent and safe procedure that may help reduce the risk of central venous stenosis from fibrin sheaths due to central venous catheters.
机译:纤维蛋白鞘是在导管周围形成的细胞和碎片的异质基质,并且是中央静脉狭窄和导管衰竭的已知原因。提出了总共50例在移除或更换导管后进行中心静脉导管纤维蛋白鞘血管成形术(FSA)的病例。对门诊数据库的回顾性研究确定了在19个月内有70名合格患者。获得知情同意后,将渗出皮肤的透析导管夹紧,截肢,然后插入一根导线。然后取下导管,将9法式护套插入上腔静脉,进行静脉造影。如果存在纤维蛋白鞘,则沿纤维蛋白鞘的整个长度使用8××4或10××4的球囊进行血管成形术。完成静脉造影以记录护套的闭塞。在研究过程中,有50例患者被诊断出纤维蛋白鞘,其中43例没有中央静脉狭窄。 FSA治疗后,在43个患者的中央系统中,有39个(91%)保持了专利,无需进行后续干预。 3名患者(占7%)出现锁骨下狭窄,需要重复进行血管成形术和支架置入术;一项专利(2.3%)开发了一种需要重新干预的闭塞技术。 7名先前有中心狭窄的患者需要进行多次血管成形术;五例需要对其中心病变置入支架。每位患者均接受了随访瘘管造影检查以记录长期通畅。我们认为,FSA是一种审慎而安全的程序,可以帮助减少由于中央静脉导管引起的纤维蛋白鞘引起的中央静脉狭窄的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号